An observational, prospective cohort study to evaluate the safety and effectiveness of Remsima® in the treatment of inflammatory bowel disease among Saudi Arabia patients diagnosed with Crohn’s disease, ulcerative colitis, or fistulizing CD

drug protocol number
RMS-KSA-20
drug sponsor
Hikma Pharmaceuticals
drug study
Remsima
drug trial site
King Abdulaziz University Hospital (Jeddah)
drug status
Ongoing
drug phase